[go: up one dir, main page]

ATE490244T1 - Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren - Google Patents

Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren

Info

Publication number
ATE490244T1
ATE490244T1 AT04704951T AT04704951T ATE490244T1 AT E490244 T1 ATE490244 T1 AT E490244T1 AT 04704951 T AT04704951 T AT 04704951T AT 04704951 T AT04704951 T AT 04704951T AT E490244 T1 ATE490244 T1 AT E490244T1
Authority
AT
Austria
Prior art keywords
compounds
methods
compositions containing
substituted pyrazoles
pyrazoles
Prior art date
Application number
AT04704951T
Other languages
English (en)
Inventor
Emma Parmee
Subharekha Raghavan
Teresa Beeson
Dong-Ming Shen
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32850762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE490244(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE490244T1 publication Critical patent/ATE490244T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04704951T 2003-01-27 2004-01-23 Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren ATE490244T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44282803P 2003-01-27 2003-01-27
PCT/US2004/001927 WO2004069158A2 (en) 2003-01-27 2004-01-23 Substituted pyrazoles, compositions containing such compounds and methods of use

Publications (1)

Publication Number Publication Date
ATE490244T1 true ATE490244T1 (de) 2010-12-15

Family

ID=32850762

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04704951T ATE490244T1 (de) 2003-01-27 2004-01-23 Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren

Country Status (8)

Country Link
US (2) US7572922B2 (de)
EP (1) EP1590336B1 (de)
JP (2) JP4560035B2 (de)
AT (1) ATE490244T1 (de)
AU (2) AU2004210127B2 (de)
CA (1) CA2513102C (de)
DE (1) DE602004030318D1 (de)
WO (1) WO2004069158A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE490244T1 (de) 2003-01-27 2010-12-15 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
EP1615895A4 (de) 2003-04-03 2007-11-07 Merck & Co Inc Biarylsubstituierte pyrazole als natriumkanalblocker
CA2566945C (en) * 2004-06-04 2010-09-21 Merck & Co., Inc. Pyrazole derivatives, compositions containing such compounds and methods of use
EP1765335B1 (de) 2004-07-07 2009-11-25 Merck & Co., Inc. Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
ATE468853T1 (de) * 2004-07-22 2010-06-15 Merck Sharp & Dohme Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
EP1896436A2 (de) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Inhibitoren der histondeacetylase
CA2613517A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
US7709658B2 (en) 2005-07-26 2010-05-04 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
WO2007111864A2 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2402320A1 (de) 2006-03-31 2012-01-04 Novartis AG Anorektische Agenten
JP2009537525A (ja) 2006-05-16 2009-10-29 メルク エンド カムパニー インコーポレーテッド グルカゴン受容体アンタゴニスト化合物、このような化合物を含む組成物及び使用方法
EP2121621B1 (de) * 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr- und fxr-modulatoren
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
KR20160052792A (ko) 2007-02-09 2016-05-12 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
BRPI0814182A2 (pt) * 2007-08-02 2015-01-27 Recordati Ireland Ltd Compostos heterocíclocos inéditos como antagonistas de mglu5
US8232413B2 (en) * 2007-09-12 2012-07-31 Merck Sharp & Dohme Corp. Process for the production of a crystalline glucagon receptor antagonist compound
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009057784A1 (ja) * 2007-11-01 2009-05-07 Takeda Pharmaceutical Company Limited 複素環化合物
AU2008340227B2 (en) 2007-12-26 2013-05-09 Elster Electricity, Llc. Optimized data collection in a wireless fixed network metering system
MX2010009736A (es) 2008-03-05 2010-09-30 Takeda Pharmaceutical Compuesto heterociclico.
US8623818B2 (en) 2008-05-16 2014-01-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
CN102089303A (zh) * 2008-07-17 2011-06-08 旭化成制药株式会社 含氮杂环化合物
CN102292316B (zh) 2008-08-13 2015-07-01 症变治疗公司 胰高血糖素拮抗剂
US8436015B2 (en) * 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2350020B1 (de) * 2008-10-03 2014-08-13 Merck Sharp & Dohme Corp. Spiro-imidazolonderivate als glucagonrezeptorantagonisten
EA201100620A1 (ru) * 2008-10-10 2011-12-30 Лонца Лтд Способ получения 2-алкил-3-ароил-5-нитробензофуранов
WO2010093535A1 (en) 2009-02-12 2010-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098994A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010144664A1 (en) * 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
EP2480077B1 (de) 2009-09-22 2015-02-18 Merck Sharp & Dohme Corp. Pyrrolidine als glucagonrezeptorantagonisten, zusammensetzungen daraus und verfahren zu ihrer verwendung
US9365539B2 (en) * 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
DK2588465T3 (en) * 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
RU2582679C2 (ru) 2010-11-09 2016-04-27 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ sGC
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
SI2673260T1 (sl) 2011-02-08 2016-10-28 Pfizer Inc. Modulator glukagonskega receptorja
AU2012288493B2 (en) 2011-07-22 2015-08-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
EP2797915B1 (de) * 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-Benzyl-3-(Oxazol/Thiazol)-5-(Pyrimidin-2-yl)-1(H)-Pyrazol-Derivate als Stimulatoren der löslichen Guanylat-Cyclase (sGC) zur Behandlung von Bluthochdruck und Herzversagen
EP3065736B1 (de) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon-rezeptor-antagonist-verbindungen, zusammensetzungen daraus und verfahren zur verwendung
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
TW201811752A (zh) * 2016-09-06 2018-04-01 比利時商健生藥品公司 用作升糖素受體拮抗劑之吲唑衍生物
TWI757332B (zh) * 2016-09-06 2022-03-11 比利時商健生藥品公司 使用作為升糖素受體拮抗劑之吲唑衍生物
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
MX2024007933A (es) * 2021-12-23 2024-08-20 Univ Leuven Kath Anilinas de 2-pirazol y analogos relacionados para inhibir yap/taz-tead.
WO2025034531A1 (en) * 2023-08-04 2025-02-13 The University Of Vermont And State Agricultural College Small molecule allosteric modulator to pac1 receptor and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
BE1009189A3 (fr) * 1995-03-14 1996-12-03 Solvay Procede pour la fabrication d'un corps creux.
WO1997016442A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
WO1998021957A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
AU730295B2 (en) 1996-11-20 2001-03-01 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
WO1998022108A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles and methods of use
EP0945438B1 (de) 1996-12-12 2003-03-05 Banyu Pharmaceutical Co., Ltd. Pyrazolderivate
PL337098A1 (en) 1997-04-18 2000-07-31 Searle & Co Method of applying the cyclooxygenase-2 inhibitors in preventing cardiovascular disorders
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
EP1042293B9 (de) 1997-12-19 2008-09-03 Amgen Inc. Substituierte pyridin- und pyridazinderivate und ihre pharmazeutische verwendung
PL346660A1 (en) 1998-09-17 2002-02-25 Bristol Myers Squibb Co Method for treating atherosclerosis employing an ap2 inhibitor and combination
JP2002544254A (ja) 1999-05-17 2002-12-24 ノボ ノルディスク アクティーゼルスカブ グルカゴンアンタゴニスト／逆アゴニスト
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
CA2381532A1 (en) 1999-08-10 2001-02-15 Akihiko Yanagi Herbicidal tetrazolinone derivatives
HK1045991B (en) * 1999-11-10 2004-12-10 Takeda Pharmaceutical Company Limited 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
MXPA02012273A (es) 2000-06-23 2003-04-25 Novo Nordisk As Antagonistas/agonistas inversos de glucagon.
ATE362468T1 (de) 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
AU2002223501A1 (en) 2000-11-17 2002-05-27 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
JP2005511683A (ja) 2001-12-03 2005-04-28 ノボ　ノルディスク　アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
AU2002351730A1 (en) 2001-12-19 2003-06-30 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
WO2003053938A1 (en) 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
US7514452B2 (en) 2002-02-01 2009-04-07 Dainippon Pharmaceutical Co., Ltd 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
AU2003249296A1 (en) 2002-07-19 2004-02-09 Baxter Healthcare S.A. Systems and methods for performing peritoneal dialysis
EP1400243A1 (de) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Aktivator von Kalzium-abhängiger Kaliumkanälen
AU2003298889A1 (en) 2002-12-04 2004-06-23 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
ATE490244T1 (de) 2003-01-27 2010-12-15 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
DE10317108A1 (de) 2003-04-14 2004-11-11 Mutzbauer, Till S., Dr. Dr.med. Transdermal applizierbares Beruhigungs- und Sedierungsmittel
ATE384526T1 (de) 2003-04-14 2008-02-15 Inst For Pharm Discovery Inc N-(((((1,3-thiazol-2- yl)amino)carbonyl)phenyl)sulphonyl)phenylalanin derivate und verwandte verbindungen zur behandlung von diabetes
CA2524436A1 (en) 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
CA2566945C (en) 2004-06-04 2010-09-21 Merck & Co., Inc. Pyrazole derivatives, compositions containing such compounds and methods of use
ATE468853T1 (de) * 2004-07-22 2010-06-15 Merck Sharp & Dohme Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
AR056574A1 (es) 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Also Published As

Publication number Publication date
EP1590336A4 (de) 2008-12-17
US7989475B2 (en) 2011-08-02
JP5260569B2 (ja) 2013-08-14
JP2006516622A (ja) 2006-07-06
JP2010150267A (ja) 2010-07-08
WO2004069158A2 (en) 2004-08-19
AU2009240856A1 (en) 2009-12-17
CA2513102C (en) 2011-03-22
EP1590336B1 (de) 2010-12-01
AU2004210127A1 (en) 2004-08-19
US20090215825A1 (en) 2009-08-27
JP4560035B2 (ja) 2010-10-13
WO2004069158A3 (en) 2005-01-20
CA2513102A1 (en) 2004-08-19
AU2004210127B2 (en) 2009-10-01
US7572922B2 (en) 2009-08-11
US20060084681A1 (en) 2006-04-20
EP1590336A2 (de) 2005-11-02
DE602004030318D1 (de) 2011-01-13

Similar Documents

Publication Publication Date Title
ATE490244T1 (de) Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
ATE468853T1 (de) Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
TW200745031A (en) Acyl indoles, compositions containing such compounds and methods of use
WO2004050039A3 (en) Spirocyclic ureas, compositions containing such compounds and methods of use
MY143599A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
WO2006104826A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
DE602004021472D1 (en) Pyrimiidinverbindungen
ATE449604T1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200505903A (en) CGRP receptor antagonists
WO2005013894A3 (en) Benzodiazepine cgrp receptor antagonists
WO2004087649A3 (en) Benodiazepine spirohydantoin cgrp receptor antagonists
DE60234616D1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
ATE479655T1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
EP1398029A8 (de) 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden
ATE383345T1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
ATE421519T1 (de) Substituierte bizyklische thiophen-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
WO2005035504A3 (en) 5-h -benzo [d] naphth [2, 1-b] azepine derivative as selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties